iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Abbvie GT4 - FDA Approved 7/28/15
 
 
  Abbvie GT4 FDA Label/PI - (07/28/15)
 
FDA approves Technivie (Abbvie 2D) for treatment of chronic hepatitis C genotype 4 - (07/28/15)
 
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial - (06/19/15) published
 
EASL/2014: RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/16/14)
 
AASLD/2014: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)
 
EASL: A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (04/23/15)
 
EASL: An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) - (04/24/15)

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org